Pfizer-biontech covid-19 vaccine receives fda emergency use authorization for children 6 months through 4 years of age

New york and mainz, germany, june 17, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the u.s. food and drug administration (fda) granted emergency use authorization (eua) of the pfizer-biontech covid-19 vaccine as a three 3-Μg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age). the 3-Μg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, and immunogenicity data.
BNTX Ratings Summary
BNTX Quant Ranking